Content about Biotechnology

July 20, 2010

Biosimilars may have cleared their biggest stretch of wilderness thanks to their inclusion in the...

July 18, 2010

Biotechnology company Spectrum Pharmaceuticals has appointed a new SVP, chief scientific officer and head of...

July 14, 2010

Watson Pharmaceuticals will work with a venture-backed firm to develop a biosimilar treatment for female...

June 27, 2010

The Food and Drug Administrations has approved two new uses for what remains, thus far,...

June 13, 2010

Indian generic drug maker Lupin is challenging a Gilead Sciences patent for a drug that...

June 7, 2010

The wholesale drug industry’s leading trade group tapped 10 pharmaceutical and consumer product manufacturers this...

June 6, 2010

After nearly a decade at the helm, Generic Pharmaceutical Association president and CEO Kathleen Jaeger...

May 24, 2010

Generic drug maker Teva Pharmaceutical Industries isn’t holding back in its effort to push into...

May 20, 2010

Abbott aims to become the top drug maker in India with the purchase of the...

May 16, 2010

Pharmaceuticals are expected to become a global market worth more than $1 trillion within four...

May 13, 2010

Teva Pharmaceutical Industries could get a lot of business thanks to the health-reform law, according...

May 9, 2010

U.S. biotechnology company Genentech and German drug maker Evotec hope to develop drugs using Evotec’s...

May 6, 2010

Pfizer reported $16.8 billion in revenues for first quarter 2010, a 54% increase over first...

March 29, 2010

Many people have a lot to say about the recently passed healthcare bill, but generic...

March 21, 2010

While calling it “not perfect,” an organization representing the country’s drug manufacturers called the healthcare-reform...

March 9, 2010

Solazyme, a renewable oil and bioproducts company, has inked a research and development agreement with...

March 4, 2010

If Medicare Part D is to remain solvent in the future, then lawmakers may want...

WHAT IT MEANS AND WHY IT'S IMPORTANT If Medicare Part D is to remain solvent in the future, then lawmakers may want to take a closer look at the more than 10% of spending on drugs under the program that has gone toward specialty drugs — some of the most expensive drugs on the market — and find ways to come up with cheaper alternatives.

March 2, 2010

An organization representing the generic drug industry is holding up a recent report by the...

February 4, 2010

GlaxoSmithKline has identified more than 5,500 rare diseases it could potentially target as part of...

February 1, 2010

The Food and Drug Administration has accepted a regulatory approval application from Teva Pharmaceutical Industries...

January 26, 2010

Lumene, a beauty brand from Finland, has launched for 2010 its new ExCELLent future deep...

January 19, 2010

Six governors are hoping to thwart an attempt by the Obama administration to eliminate language...

January 14, 2010

As the House and Senate fuse their respective healthcare-reform bills into one, a push has...

January 11, 2010

AmerisourceBergen announced a new program for long-term care pharmacies and an expanded program for retail...

August 20, 2009

Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody”...

NEW YORK Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody” means, but they know that battling a chronic disease can be a frightening and financially devastating prospect. Teva’s new TV campaign is a very sobering reminder of what many already know at a time when all of America is focused on fixing health care.